Quercetin for Cancer

The Bottom Line

Quercetin is a flavonoid antioxidant found in foods like onions, apples, capers, and dark berries. It is one of the most studied natural compounds for cancer prevention and has recently gained attention as a senolytic agent — meaning it can selectively kill senescent ("zombie") cells that accumulate with age and drive chronic inflammation and tumor progression. The combination of quercetin with the leukemia drug dasatinib (D+Q) has become one of the most researched senolytic protocols in the longevity field. However, quercetin's extremely poor oral bioavailability (less than 5%) is a significant obstacle to achieving the plasma concentrations needed for its anticancer effects, and large human cancer trials are lacking.

What Quercetin Is

Quercetin (3,3',4',5,7-pentahydroxyflavone) is a flavonol — a subclass of flavonoids. It is one of the most abundant dietary flavonoids, with typical intakes of 10–40 mg/day in people eating a plant-rich diet. Supplements often contain quercetin dihydrate. It has been studied for over 50 years, initially as a mast cell stabilizer (used in Japan for allergic conditions), later as an antioxidant, and most recently as a senolytic and anticancer agent.

Dietary Sources

• Capers: Among the highest quercetin foods (~234 mg per 100g fresh weight)
• Onions (red): (~40–120 mg/100g, highest in outer layers)
• Apples (with skin): (~30 mg/100g)
• Dark berries:尤其是蓝莓、黑加仑 (15–30 mg/100g)
• Citrus fruits: Lower amounts
• Teas and wines: Minor contributors

How It Works Against Cancer

• Senolytic activity: Quercetin (especially combined with dasatinib) kills senescent cells by inhibiting PI3K/Akt and other survival pathways. Senescent cells secrete SASP factors (IL-6, IL-8, MMPs) that promote tumor growth, angiogenesis, and metastasis. Removing them may slow cancer progression.
• PI3K/Akt inhibition: One of the most important oncogenic pathways. Quercetin inhibits PI3K, Akt, and mTOR — key nodes in the cell growth and survival machinery of cancer cells.
• Autophagy modulation: Induces protective autophagy at low concentrations, but at higher concentrations blocks autophagic flux, pushing cancer cells toward death.
• Apoptosis induction: Activates both intrinsic (mitochondrial) and extrinsic (death receptor) pathways. Upregulates p53, Bax, and caspases; downregulates Bcl-2.
• Angiogenesis inhibition: Downregulates VEGF, HIF-1α, and other angiogenic factors.
• Cell cycle arrest: Stops cancer cells at G1/S or G2/M checkpoints.
• Antioxidant activity: Paradoxically, quercetin is a potent antioxidant in normal cells, but can pro-oxidantly generate cytotoxicity in cancer cells ( redox modulation).
• Immune modulation: Modulates NK cell activity, macrophage polarization, and T-cell function.

The Senolytic Breakthrough — D+Q Combination

The combination of Dasatinib (a tyrosine kinase inhibitor) and Quercetin (D+Q) is the senolytic protocol that has generated the most scientific interest. Research from Kirkland and Tchkonia at the Mayo Clinic established that many FDA-approved drugs can be screened for senolytic activity — and D+Q was one of the first combinations to show robust, reproducible results.

The key insight: senescent cells depend on survival pathways (particularly Akt and PI3K) to resist apoptosis. Quercetin inhibits some of these pathways; dasatinib inhibits others. Together, they create a "one-two punch" that overwhelms the senescent cell's defenses.

• D+Q reduces senescent cell burden in multiple tissues in animal models by 50–80%
• SASP reduction — decreased IL-6, IL-8, PAI-1, and other pro-tumorigenic factors
• In aging humans, D+Q reduced senescence markers in skin (published in Aging Cell)
• Phase I trial in idiopathic pulmonary fibrosis (IPF) — published in EBioMedicine (Lancet subsidiary). 14 patients received D+Q for 3 days. Improved physical function (6-minute walk distance). This was the first human senolytic trial and established proof-of-concept for the D+Q combination.

The Bioavailability Problem

Quercetin's major limitation is its extremely poor oral bioavailability, estimated at less than 5% in most studies. This is due to:

• Low intestinal absorption
• Rapid metabolism (sulfation, glucuronidation in the gut and liver)
• Poor aqueous solubility

Quercetin metabolites (particularly quercetin-3-O-glucuronide) may have biological activity, but it's unclear if they match the parent compound's potency. Formulations designed to improve bioavailability (liposomes, phytosomes, nanoparticles) and alternative routes of administration (IV) are active areas of research. High-dose supplementation (1–2g/day) is required to achieve even modest plasma levels.

Phase I Senolytic Trials

The first human senolytic trial (D+Q, n=14, IPF) established safety and demonstrated functional improvement. Subsequent trials have explored:

• Diabetic kidney disease: D+Q improved kidney function markers (eGFR)
• Bone marrow transplant survivors: Reduced senescent T-cells and SASP factors
• Alzheimer's disease (REJUVENATRON trial): Ongoing

No large-scale cancer-specific trials have been completed. The senolytic hypothesis for cancer is compelling — senescent cells in the tumor microenvironment clearly drive tumor progression — but translating this to cancer treatment requires dedicated trials.

Protocol Considerations

• For senolytic effect: D+Q protocol — Dasatinib 100mg + Quercetin 1250mg, taken once daily for 2–3 days. This is the Mayo Clinic protocol. Courses are repeated periodically (every few months for "healthspan" purposes).
• For general health: Quercetin 500–1000mg daily (much higher than dietary intake), but recognizing bioavailability limitations
• Bioavailability enhancement: Some protocols use bromelain (from pineapple) or vitamin C to improve absorption; evidence is mixed
• With food: Fat improves absorption somewhat

Safety Profile

• Generally well-tolerated in doses up to 5g/day short-term
• At high doses: headache, GI upset, paresthesia
• Quercetin may have estrogenic activity at very high doses (relevance for hormone-sensitive cancers uncertain)
• Drug interactions: Quercetin inhibits CYP3A4 and other enzymes; interaction potential with chemotherapy agents
• Dasatinib side effects include fluid retention, myelosuppression, QT prolongation — these are significant and require monitoring when used as D+Q

Our Assessment

Quercetin is genuinely interesting science, particularly as a senolytic and as a PI3K/Akt inhibitor. The D+Q combination has moved from mice to humans faster than almost any other senolytic intervention, and the IPF trial data (improved physical function) is encouraging. However, the cancer-specific evidence remains preclinical and the bioavailability problem is real. As a long-term healthspan supplement, quercetin is relatively safe and may have preventive value. As a standalone cancer treatment, it is not established. May have value as an adjunct in senolytic-focused cancer protocols, particularly for patients with evidence of elevated senescence burden.

Sources

• PMC6027984: "Dasatinib and quercetin as a senolytic combination" (2018)
• EBioMedicine (Lancet): First human senolytic trial in IPF (2019)
• PMC6953936: Quercetin anticancer mechanisms review (2020)
• PMC6422027: PI3K/Akt/mTOR inhibition by quercetin
• PMC6310908: Bioavailability challenges and formulation strategies
• PMC10465189: D+Q senolytic trial in diabetic kidney disease (2023)